Controlled attenuation parameter (CAP): A new device for fast evaluation of liver fat?

Liver International

Volumn 32, Issue 6, 2012, Pages 875-877

  Boursier, Jérôme ^a,b   Calès, Paul ^a,b  

^a LUNAM University   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL ABUSE; BLOOD ANALYSIS; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ECHOGRAPHY; EDITORIAL; FATTY LIVER; HEALTH CARE COST; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT SAFETY; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIRUS HEPATITIS;

ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE;

EID: 84861961267     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02824.x     Document Type: Editorial

References (20)

1. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
2. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
3. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010; 16: 874-84.
4. de Meijer VE, Kalish BT, Puder M, Ijzermans JN. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 2010; 97: 1331-9.
5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
6. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008; 28: 386-95.
7. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.
8. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
9. Guiu B, Loffroy R, Hillon P, Petit JM. Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: urgent need for standardization! J Hepatol 2009; 51: 1082-3.
10. Miller MH, Ferguson MA, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 2011; 31: 461-73.
11. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
12. de Ledinghen V, Vergniol J, Foucher J, Merrouche L, le Bail B. Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-8.
13. Myers RP, Pollett A, Pomier-Layrargues G, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-10.
14. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-35.
15. de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan. J Hepatol 2012; 56: 833-9.
16. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the Fibroscan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
17. Cales P, Veillon P, Konate A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-18.
18. Boursier J, Konate A, Gorea G, et al. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 2008; 6: 1263-9.
19. Boursier J, Bertrais S, Oberti F, et al. Comparison of accuracy of fibrosis degree classifications by liver biospy and non invasive tests in chronic hepatitis C. BMC Gastroenterol 2011; 30: 132.
20. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan: validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-53.